Short answer
REGENXBIO Inc. (RGNX) filed an 8-K current report with the SEC on June 3, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders), Item 8.01 (Other Events). 2026 annual meeting participation: 42,818,883 shares, representing 82.95% of eligible shares.
REGENXBIO Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 2026 annual meeting participation: 42,818,883 shares, representing 82.95% of eligible shares
- Class II directors Jean Bennett, Jerry Karabelas, and Daniel Tassé elected through 2029
- PwC auditor appointment ratified with 42,526,553 votes for and 244,785 against
- Executive compensation approved advisory basis, with 32,392,302 votes for
- Employee option exchange approved, while executive option exchange rejected 21,021,531 to 14,097,815
Item 8.01 · Other Events
- Stock option exchange launched June 3, 2026 for non-executive employees, following shareholder approval
- Eligible options require exercise prices of at least $18.00 under the 2015 Equity Incentive Plan
- Exchange period ends July 1, 2026 unless extended
- Replacement options carry reduced quantities and exercise prices tied to fair market value
- Company expects no significant change in stock compensation expense
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other REGENXBIO Inc. 8-K filings
Get the next RGNX 8-K as it lands
Follow RGNX for push alerts, or ask the research agent what this filing means.